AQST director sells 25,000 shares after option exercise
Aquestive Therapeutics director Julie Krop exercised and sold company stock under a pre-set trading plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Aquestive Therapeutics director Julie Krop exercised and sold company stock under a pre-set trading plan. On June 23, 2026, she exercised options for 25,000 shares of common stock at $0.7132 per share, then sold 25,000 shares at an average price of $5.0157 in an open-market transaction.
Both the option exercise and the sale were carried out pursuant to a previously adopted Rule 10b5-1 trading plan. Following these transactions, the filing shows 0 shares of common stock held directly and no remaining listed derivative positions.
Insider Trade Summary 10b5-1
Exercise and Sale: 25,000 shares ($108K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Krop Julie
Role
Director
Sold
25,000 shs ($125K)
Approx. gross sale proceeds
$125K
Approx. exercise cost
$18K
Approx. pre-tax spread
$108K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 25,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 25,000 | $0.7132 | $18K |
| Sale | Common Stock | 25,000 | $5.0157 | $125K |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 0 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (3)
- F1. This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected.
- F2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.
- F3. This option was granted on June 22, 2022 and is fully vested.
Key Figures
Shares sold: 25,000 shares
Sale price: $5.0157 per share
Options exercised: 25,000 shares
+2 more
5 metrics
Shares sold
25,000 shares
Common stock sold in open-market transaction on June 23, 2026
Sale price
$5.0157 per share
Average price for 25,000 common shares sold
Options exercised
25,000 shares
Non-Qualified Stock Option exercised into common stock
Exercise price
$0.7132 per share
Exercise price of Non-Qualified Stock Option granted June 22, 2022
Post-transaction holdings
0 shares
Common stock directly held after transactions
Key Terms
Rule 10b5-1 Trading Plan, Non-Qualified Stock Option, open-market sale, derivative security, +1 more
5 terms
Rule 10b5-1 Trading Plan regulatory
"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Form 4 regulatory
"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Aquestive Therapeutics (AQST) director Julie Krop report?
Director Julie Krop reported exercising options for 25,000 Aquestive Therapeutics shares and selling 25,000 common shares. The option exercise and subsequent open-market sale occurred on June 23, 2026, as disclosed in a Form 4 insider trading report.
What stock options did Julie Krop exercise in the Aquestive Therapeutics (AQST) Form 4?
She exercised a Non-Qualified Stock Option covering 25,000 shares of Aquestive Therapeutics common stock at an exercise price of $0.7132 per share. The option was originally granted on June 22, 2022 and was fully vested at the time of exercise.
Were Julie Krop’s Aquestive Therapeutics (AQST) trades made under a Rule 10b5-1 plan?
Yes. The Form 4 footnotes state that both the scheduled option exercise and the sales were effected pursuant to a previously adopted Rule 10b5-1 trading plan. Such plans pre-schedule trades, reducing the significance of transaction timing.
What do the transaction codes S and M mean in the Aquestive Therapeutics (AQST) Form 4?
Code “S” indicates a sale in the open market or a private transaction, which covered 25,000 common shares. Code “M” indicates an exercise or conversion of a derivative security, here representing the exercise of options into 25,000 common shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates